BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 29155186)

  • 1. Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings.
    Bjurlin MA; Rosenkrantz AB; Sarkar S; Lepor H; Huang WC; Huang R; Venkataraman R; Taneja SS
    Urology; 2018 Feb; 112():112-120. PubMed ID: 29155186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toward an MRI-based nomogram for the prediction of transperineal prostate biopsy outcome: A physician and patient decision tool.
    Lee SM; Liyanage SH; Wulaningsih W; Wolfe K; Carr T; Younis C; Van Hemelrijck M; Popert R; Acher P
    Urol Oncol; 2017 Nov; 35(11):664.e11-664.e18. PubMed ID: 28801025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
    Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram.
    Bjurlin MA; Renson A; Rais-Bahrami S; Truong M; Rosenkrantz AB; Huang R; Taneja SS
    Eur Urol Focus; 2019 Sep; 5(5):815-822. PubMed ID: 29802053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study.
    Falagario U; Jambor I; Taimen P; Syvänen KT; Kähkönen E; Merisaari H; Montoya Perez I; Knaapila J; Steiner A; Verho J; Tewari A; Aronen HJ; Carrieri G; Boström PJ; Ettala O
    World J Urol; 2021 Jun; 39(6):1879-1887. PubMed ID: 32778912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-institutional nomogram predicting benign prostate pathology on magnetic resonance/ultrasound fusion biopsy in men with a prior negative 12-core systematic biopsy.
    Truong M; Wang B; Gordetsky JB; Nix JW; Frye TP; Messing EM; Thomas JV; Feng C; Rais-Bahrami S
    Cancer; 2018 Jan; 124(2):278-285. PubMed ID: 28976544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric MRI in detection and staging of prostate cancer.
    Boesen L
    Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Real-time MRI/US fusion-guided biopsy improves detection rates of prostate cancer in pre-biopsied patients].
    Maxeiner A; Fischer T; Stephan C; Cash H; Slowinski T; Kilic E; Durmus T
    Aktuelle Urol; 2014 May; 45(3):197-203. PubMed ID: 24902069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.
    Sonn GA; Chang E; Natarajan S; Margolis DJ; Macairan M; Lieu P; Huang J; Dorey FJ; Reiter RE; Marks LS
    Eur Urol; 2014 Apr; 65(4):809-15. PubMed ID: 23523537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
    Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
    Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.
    Shukla-Dave A; Hricak H; Akin O; Yu C; Zakian KL; Udo K; Scardino PT; Eastham J; Kattan MW
    BJU Int; 2012 May; 109(9):1315-22. PubMed ID: 21933336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are concurrent systematic cores needed at the time of targeted biopsy in patients with prior negative prostate biopsies?
    Albisinni S; Aoun F; Noel A; El Rassy E; Lemort M; Paesmans M; van Velthoven R; Roumeguère T; Peltier A
    Prog Urol; 2018 Jan; 28(1):18-24. PubMed ID: 29203158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical prediction tool to determine the need for concurrent systematic sampling at the time of magnetic resonance imaging-guided biopsy.
    Sathianathen NJ; Warlick CA; Weight CJ; Ordonez MA; Spilseth B; Metzger GJ; Murugan P; Konety BR
    BJU Int; 2019 Apr; 123(4):612-617. PubMed ID: 30417504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A predictive model based on biparametric magnetic resonance imaging and clinical parameters for improved risk assessment and selection of biopsy-naïve men for prostate biopsies.
    Boesen L; Thomsen FB; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thomsen HS; Jakobsen H
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):609-616. PubMed ID: 30988407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of free-hand transperineal targeted prostate biopsy using multiparametric magnetic resonance imaging-transrectal ultrasound fusion in Chinese men with prior negative biopsy and elevated prostate-specific antigen.
    Lian H; Zhuang J; Wang W; Zhang B; Shi J; Li D; Fu Y; Jiang X; Zhou W; Guo H
    BMC Urol; 2017 Jul; 17(1):52. PubMed ID: 28679370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the addition of targeted prostate biopsies to standard systemic biopsies influence treatment management for radiation oncologists?
    Kamrava M; Hegde JV; Abgaryan N; Chang E; Le JD; Wang J; Kupelian PA; Marks LS
    BJU Int; 2016 Apr; 117(4):584-91. PubMed ID: 25684394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing detection of clinically significant prostate cancer through nomograms incorporating mri, clinical features, and advanced serum biomarkers in biopsy naïve men.
    Siddiqui MR; Li EV; Kumar SKSR; Busza A; Lin JS; Mahenthiran AK; Aguiar JA; Shah PV; Ansbro B; Rich JM; Moataz SAS; Keeter MK; Mai Q; Mi X; Tosoian JJ; Schaeffer EM; Patel HD; Ross AE
    Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):588-595. PubMed ID: 36973367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
    Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
    Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Real-time MRI/US fusion-guided biopsy in biopsy-naïve and pre-biopsied patients with suspicion for prostate cancer].
    Maxeiner A; Stephan C; Fischer T; Durmus T; Kilic E; Asbach P; Haas M; Günzel K; Neymeyer J; Miller K; Cash H
    Aktuelle Urol; 2015 Jan; 46(1):34-8. PubMed ID: 25519051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.